Concepedia

Gil-Jong Kang

GK

Statistics

Publications

6

Citations

573

H-Index

6

Active since

1984

Affiliations

National Cancer Institute(Current)

Gil-Jong Kang is an author at National Cancer Institute specializing in enzyme inhibition, medicine, and nucleoside analogs.

Publications per year

1984–1989

6

Publications

6

The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides.

Jan Balzarini, Gil-Jong Kang, Maha Dalal et al. · Molecular Pharmacology · 1987 · 234 citations

Medicine, Medicinal Chemistry, Pharmacology +14

Potent and selective anti-HTLV-IIILAV activity of 2′,3′-dideoxycytidinene, the 2′,3′-unsaturated derivative of 2′,3′-dideoxycytidine

Jan Balzarini, Rudi Pauwels, Piet Herdewijn et al. · Biochemical and Biophysical Research Communications · 1986 · 130 citations

Life Sciences, Medicinal Chemistry, Pharmacology +13

Cyclopentenylcytosine Triphosphate

Gil-Jong Kang, David A. Cooney, James D. Moyer et al. · Journal of Biological Chemistry · 1989 · 91 citations · Full text

Life Sciences, Biochemistry, Cell Biology +13

2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis.

Jan Balzarini, David A. Cooney, Maha Dalal et al. · Molecular Pharmacology · 1987 · 75 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.

Gil-Jong Kang, A. P. Kimball · PubMed · 1984 · 23 citations

Medicine, Biochemistry, Oncology +9

1–5 of 6